Results 191 to 200 of about 3,492,274 (391)

Clinical analysis of anti⁃leucine⁃rich glioma⁃inactivated 1 antibody⁃related encephalitis

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2020
Objective To explore the clinical characteristics of anti⁃leucine⁃rich glioma⁃inactivated 1 (LGI1) antibody⁃related encephalitis. Methods and Results Clinical data of 6 patients with anti⁃LGI1 antibody⁃related encephalitis from September 2016 to April ...
Qing⁃qing ZHAO   +4 more
doaj  

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

open access: yesMolecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho   +11 more
wiley   +1 more source

Adjuvants : an essential component of neisseria vaccines [PDF]

open access: yes, 2009
Adjuvants may be classified into delivery systems and immune potentiator or modulator molecules based on their mechanism of action. Neisseria vaccines containing traditional adjuvants such as aluminium salts have existed for long time, but meningitis ...
Acevedo, R.   +8 more
core  

The future of neuroimmunology

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2020
Neuroimmunology is one of the most potential fields of brain science, which challenges the neurologists. The development of antibody spectrum, the deepening research of mechanism and the precision of treatment make the future of this field full of ...
Sheng CHEN, Qin⁃ming ZHOU, You NI
doaj  

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections? [PDF]

open access: yes, 2017
Nontuberculous mycobacteria (NTM) are categorized as one of the large and diverse groups of environmental organisms which are abundant in water and soil.  NTM cause a variety of diseases in humans that mainly affect the lung.
Adcock, IM   +7 more
core  

Home - About - Disclaimer - Privacy